Brief: Longboard Pharmaceuticals Provides Corporate Update And Reports First Quarter 2023 Financial Results
09/05/2023 21:45
May 9 (Reuters) - Longboard Pharmaceuticals Inc
LBPH.O :
* LONGBOARD PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND
REPORTS
FIRST QUARTER 2023 FINANCIAL RESULTS
* AT MARCH 31, 2023, LONGBOARD'S CASH, CASH EQUIVALENTS AND
SHORT-TERM INVESTMENTS WERE APPROXIMATELY $76.1 MILLION
* CASH RUNWAY IS EXPECTED TO SUPPORT OPERATIONS INTO
MID-2024
* LP352 PHASE 1B/2A PACIFIC STUDY TOPLINE DATA EXPECTED IN
Q4 2023
* QTRLY LOSS PER SHARE $0.56
* Q1 EARNINGS PER SHARE VIEW $-0.57 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw1VFRTka
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions